Do xanthine oxidase inhibitors regress left ventricular hypertrophy in diabetes? A whole new approach to reducing cardiac deaths

Phase 4

Completed

• Conditions: eft ventricular hypertrophy; Circulatory System; Hypertensive heart disease

• Registration Number: ISRCTN96755104
• Lead Sponsor: niversity of Dundee (UK)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-04-20
• Last Update Posted: 17 October 2016

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 66

Inclusion Criteria

1. Patients with type 2 diabetes
2. Patients with left ventricular hypertrophy
3. Office target blood pressure less than 150/90 mmHg at recruitment

No age or gender restrictions.

Exclusion Criteria

1. Gout
2. Already on allopurinol
3. Previous adverse reaction to allopurinol
4. Poor kidney function (estimated glomerular filtration rate [eGFR] less than 60 ml/mm)
5. Conditions that exclude magnetic resonance imaging (MRI)
6. Heart failure (left ventricular ejection fraction [LVEF] less than 45%)
7. Cancer or other life threatening illness
8. Pregnancy or breast feeding
9. Unable to provide consent

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
To assess if allopurinol reduces left ventricular hypertrophy in patients with diabetes

Secondary Outcome Measures

Name	Time	Method
1. To assess if allopurinol improves endothelial function in diabetic patients will be done with flow mediated dilatation (FMD) and sphygmocor measurements. These tests will be done at time 0, 6 months and 1 year.<br>2. To assess if allopurinol reduces arrthymogenicity in diabetic patients will be done with a technique called microvolt T wave alternans (MTWA). This test will be done at time 0 and 1 year.